For chronic pain sufferers, there is a real problem with the abuse of painkillers in the United States. While the number of patients who have a legitimate need for prescription painkillers — 100 million plus — is vastly more than the number of people addicted to painkillers — 11 million — there is a stigma attached to the prescribing, dispensing and utilization of pain medicines.
News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.
Alcon, a division of Novartis, has announced the U.S. launch of Clear Care Plus Cleaning & Disinfecting Solution containing HydraGlyde Moisture Matrix technology for cleaning and disinfecting contact lenses.
Aurobindo Pharma Limited has announced that it has received final approval from the U.S. Food and Drug Administration for entacapone tablets USP, 200 mg, the generic equivalent to Comtan Tablets 200 mg.
Executives from SoapBox Soaps, one of the recent winners of the Drug Store News’ Best New Product award at ECRM’s 2015 Skin, Bath, Cosmetics & Fragrances event, explain the mission behind their products and why product quality is so important.
The FDA announced on Tuesday that it determined that partially hydrogenated oils, the primary dietary source of artificial trans fat in processed foods, are not generally recognized as safe for use in human food.
Loblaw has announced that by the end of 2018, its private brands Life Brand and President's Choice household, beauty and cosmetic products will no longer be formulated using triclosan, phthalates or micro beads.
Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility.